The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with benign prostatic hyperplasia (BPH).
Manufactured by NeoTract, the UroLift System relieves urine flow by pulling back prostate tissue pressing on the urethra.
The FDA describes the device as a less invasive alternative to surgery for BPH treatment and an option for men who cannot tolerate available drug therapies.
From the November 01, 2013 Issue of Renal and Urology News
Next post in News in Brief
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.